# **Equity Research**

May 16, 2021 BSE Sensex: 48733

**ICICI Securities Limited** is the author and distributor of this report

Q4FY21 result review and earnings revision

# **Pharmaceuticals**

Target price: Rs5,848

#### Earnings revision


FY22E	FY23E
(0.2)	0.4
0.6	2.7
	(0.2)

Target price revision Rs5,848 from Rs5,528

### Shareholding pattern

	Sep '20	Dec '20	Mar 21
Promoters	26.7	26.7	26.7
Institutional			
investors	43.6	43.9	44.0
MFs and others	11.4	13.3	13.3
Insurance Cos.	2.4	1.1	1.0
FIIs	29.8	29.5	29.7
Others	29.7	29.4	29.3
Source: BSE India			

### **Price chart**



## **Research Analysts:**

Sriraam Rathi sriraam.rathi@icicisecurities.com +91 22 6637 7574 Vinay Bafna vinay.bafna@icicisecurities.com

+91 22 6637 7339

# **Dr. Reddy's Laboratories**

*ICICI*Securities Maintained Rs5.196

# Steady quarter; outlook intact

INDIA

Dr. Reddy's Laboratories' (DRL) reported Q4FY21 performance broadly in-line with our estimates. Revenue grew 6.7% YoY to Rs47.3bn (I-Sec: Rs48.5bn) driven by India, EU and ROW markets. EBITDA margin at 21.5% was lower 130bps QoQ due to lower sales. Adjusted PAT declined 13.1% to Rs5.5bn (I-Sec: Rs5.4bn) due to higher tax rate. US sales improved 1.7% QoQ to US\$239mn led by new launches. We expect the growth momentum in branded generics business (India & EMs) and new launches in US to continue in coming quarters supporting growth. Management expects to launch generic Vascepa in next two months with smooth API supplies. DRL has launched Sputnik V vaccine in India which would provide significant upside to earnings in near term. Retain ADD.

- ▶ India remains strong, US stable: India sales grew 23.5% YoY with consolidation of Wockhardt products which was completed in Jun'20 and recovery in industry growth. Adjusting for Wockhardt integration growth stood at  $\sim$ 8% during the guarter and  $\sim$ 2% for the year. US revenue improved 1.7% QoQ to US\$239mn vs estimated US\$240mn led by new product launches. We believe recent launch of *Ciprodex* and expectation of Vascepa launch in near term would help in improving revenue run-rate. PSAI business segmented reported growth of 10.0% YoY led by better volumes. EU generics reported strong 14.8% growth led by new launches and traction in volumes. EM revenues grew 10.0% led by CIS and ROW with new launches and strong traction in volumes.
- **Increase in cost base continued:** Gross margin was sequentially stable at 53.7%, in line with estimate and it has improved by 220bps YoY led by improved business and product mix. However, EBITDA margin dropped 130bps QoQ to 21.5% (I-Sec: 21.7%) due to lower sales and higher R&D spend. S,G&A expenses sequentially grew ~14% in Q3FY21 and this high base has sustained in Q4FY21 led by incremental expenses post Wockhardt acquisition and higher freight charges. Gross margin has been volatile on quarterly basis but we expect it to remain ~54-56%.
- Outlook: Overall, we expect revenues and earnings to grow at 14.3% and 35.4% CAGRs, respectively, over FY21-FY23E with 610bps EBITDA margin expansion. Our estimates include upside from Revlimid in H2FY23E. The focus of the management continues to improve EBITDA margin to ~25% and RoCE through better capital allocation. The company has launches Sputnik V in India and may export it as well. This can provide significant upside in near term to our estimates.
- Valuations and risks: We marginally raise earnings estimates by 1-3% for FY22E-FY23E to factor-in higher other income. We value Sputnik V opportunity at Rs144/share on NPV basis for next three years. Maintain ADD on the stock with a revised target price of Rs5,848/share based on 25xFY23E EPS, an additional Rs330/share for *Revlimid* and NPV of Rs144 for Sputnik V vaccine (earlier: Rs5,528/share). Key downside risks: delay in launching new products, regulatory hurdles and currency volatility.

Market Cap	Rs864bn/US\$11.8bn	Year to Mar	FY20	FY21	FY22E	FY23
Reuters/Bloomberg	REBY.BO/DRRD IN	Revenue (Rs mn)	167,371	189,722	210,285	247,94
Shares Outstanding (mr	ו) 166.3	Net Income (Rs mn)	19,497	19,149	30,367	47,511
52-week Range (Rs)	5417/3679	EPS (Rs)	112.0	156.1	182.9	286.2
Free Float (%)	73.3	% Chg YoY	9.7	39.4	17.2	56.5
FII (%)	29.7	P/E (x)	46.4	33.3	28.4	18.2
Daily Volume (US\$/'000	) 86,179	CEPS (Rs)	187.1	232.6	261.0	365.7
Absolute Return 3m (%)	) 8.4	EV/E (x)	24.3	19.2	16.6	11.0
Absolute Return 12m (%	ó) 40.1	Dividend Yield (%)	0.4	0.5	0.6	1.0
Sensex Return 3m (%)	(5.3)	RoCE (%)	10.3	13.4	13.8	19.0
Sensex Return 12m (%)	) 58.3	RoE (%)	12.6	15.7	16.2	21.8

Please refer to important disclosures at the end of this report

# Highlights of Q4FY21 result and earnings call

- Net sales grew 6.7% YoY to Rs47.3bn.
  - Global generics' revenue grew 6.4% YoY driven by growth in India.

**North America** sales declined 3.2% YoY (+0.6% QoQ) to Rs17.5bn. In constant currency, it grew 1.7% QoQ to US\$239mn led by six new launches and traction in the existing portfolio. Cumulatively, the company has 95 ANDAs {including three NDAs under 505(b)(2)} pending for approval, of which 47 are Para IV, and 23 are believed to have First to File (FTF) status. Company is gearing up to launch generic *Vascepa* with smooth API supply. Company has responded to Nuvaring CRL and expects some feedback from the regulator by Q3FY22. Compay is still working on the *Copaxone* CRL. It is unlikely that these two products will launch in FY22.

- India sales grew 23.5% YoY (-11.9% QoQ) to Rs8.4bn. The growth was due to integration of Wockhardt India portfolio which was recently acquired. Adjusting for it, growth stood at ~8% during the quarter and ~2% for the year. Sequential declined was due to fall in demand for COVID-19 portfolio. Company has launched its *Sputnik V* vaccine in India. Company is entitled to sell 250mn doses in India and it believes that local manufacturing will start Aug'21 onwards. Till then the vaccine will be imported from Russia. Company is also in discussion with RDIF for *Sputnik Light* and permission to export the vaccines.
- Europe sales grew 14.8% YoY (-4.5% QoQ) to Rs4.0bn with new launches and volume traction across markets. Company launched products in Germany, UK, Italy and Spain.
- Emerging markets (Russia, CIS and RoW) sales grew 10.0% YoY.
  - **Russia and CIS sales:** Russia sales grew 2.6% YoY led by gradual recovery in volumes and new launches. CIS and Romania sales grew 5.6% to Rs1.9bn with new launches and higher volume.
  - **RoW sales** grew 25.7% YoY to Rs3.0bn led by new launches and volume traction in new markets as well as in base business.
- PSAI segment grew 10.0% YoY (+12.9% QoQ) to Rs7.9bn supported by recovery in volumes, launch of new products and forex movement. The company filed 14 DMFs in the US during the year.
- **PP segment** declined 12.8% YoY and 58.9% QoQ to Rs632mn.
- **Gross margin** was stable at 53.7% QoQ but it improved by 220bps YoY led by improved business and product mix. However, EBITDA margin dropped 130bps QoQ to 21.5% due to lower sales and higher R&D spend. **R&D expenses** stood at 8.7% of net sales.
- Adjusted PAT declined 13.1% YoY to Rs5.5bn. Capex during the quarter stood at Rs2.9bn.

## Table 1: Q4FY21 result review

(Rs mn, year ending March 31)

	Q4FY21	Q4FY20	YoY % Chg	Q3FY21	QoQ % Chg
Net Sales	47,284	44,318	6.7	49,296	(4.1)
Gross Profit	25,375	22,808	11.3	26,538	(4.4)
EBITDA	10,171	9,406	8.1	11,260	(9.7)
Other income	766	273	180.6	279	174.6
PBIDT	10,937	9,679	13.0	11,539	(5.2)
Depreciation	3,169	2,965	6.9	3,217	(1.5)
Interest	(318)	(435)	(26.9)	(493)	(35.5)
Extra ordinary income/ (exp.)	(15)	1,257	. ,	(5,972)	. ,
PBT	8,071	8,406	(4.0)	2,843	183.9
Тах	2,536	764	231.9	2,645	(4.1)
Reported PAT	5,535	7,642	(27.6)	198	2,695.5
Adjusted PAT	5,545	6,384	(13.1)	6,170	(10.1)
EBITDA margins (%)	21.5	21.2	30bps	22.8	(130)bps

Source: Company data, I-Sec research

## Table 2: Revenue mix

(Rs mn, year ending March 31)

	Q4FY21	Q4FY20	YoY % Chg	Q3FY21	QoQ % Chg
Global Generics	38,737	36,399	6.4	40,751	(4.9)
North America	17,491	18,072	(3.2)	17,394	0.6
Europe	3,956	3,446	14.8	4,143	(4.5)
India	8,445	6,839	23.5	9,591	(11.9)
Russia & Other CIS	5,900	5,700	3.5	6,600	(10.6)
ROW	2,945	2,342	25.7	3,023	(2.6)
PSAI	7,915	7,195	10.0	7,009	12.9
Proprietary Products & others	632	725	(12.8)	1,536	(58.9)
Total	47,284	44,319	6.7	49,296	(4.1)

Source: Company data, I-Sec research

# Table 3: Segment gross margin

(%, year ending	March 31)	
-----------------	-----------	--

Segment Gross Margin	Q4FY21	Q4FY20	YoY % Chg	Q3FY21	QoQ % Chg
Global Generics	57.9	55.9	200bps	57.6	30bps
PSAI	31.7	28.4	330bps	25.3	640bps

Source: Company data, I-Sec research

# Valuations

Overall, we expect revenues and earnings to grow at 14.3% and 35.4% CAGRs, respectively, over FY21-FY23E with 610bps EBITDA margin expansion. The stock currently trades at 28.4xFY22E and 18.2xFY23E earnings and EV/EBITDA multiple of 16.6xFY22E and 11.0xFY23E. We expect the growth momentum in branded generics business (India & EMs) and new launches in US to continue in coming quarters supporting growth. Management expects to launch generic *Vascepa* in next two months with smooth API supplies. DRL has launched *Sputnik V* vaccine in India which would provide significant upside to earnings in near term. We retain **ADD** with a revised target price of Rs5,848/share based on 25xFY23E EPS, an additional Rs330/share for *Revlimid* and NPV of Rs144 for *Sputnik V* vaccine (earlier: Rs5,528/share).





Source: Company data, I-Sec research

# **Financial summary**

### **Table 4: Profit and loss statement**

(Rs mn, year ending March 31)

	FY20	FY21	FY22E	FY23E
Global Generics	138,123	154,404	170,733	204,634
PSAI	25,747	31,982	36,075	39,683
Proprietary Products	671	523	523	523
Others	2,830	2,813	2,954	3,101
Net Sales	167,371	189,722	210,285	247,941
Total Revenue	167,371	189,722	210,285	247,941
yoy Growth%	10.1	13.4	10.8	17.9
Total Op. Exp.	132,047	145,049	160,028	174,655
EBITDA	35,324	44,673	50,257	73,286
Margins %	21.1	23.5	23.9	29.6
yoy Growth%	19.6	26.5	12.5	45.8
Depn. & Amortisation	12,472	12,696	12,955	13,204
EBIT	22,852	31,977	37,301	60,083
Other Inc/Interest (net)	2,869	3,115	3,188	3,265
Extraordinary Items	(7,690)	(6,768)	0	0
PBT	18,031	28,324	40,490	63,347
Тах	4,998	9,175	10,122	15,837
Tax Rate (%)	27.7	32.4	25.0	25.0
Minority Interest	(6,464)	-	-	-
Reported PAT	19,497	19,149	30,367	47,511
Adjusted PAT	18,591	25,917	30,367	47,511
Net Margins (%)	11.1	13.7	14.4	19.2

Source: Company data, I-Sec research

# Table 5: Balance sheet

#### (Rs mn, year ending March 31)

<u>i to mili jour onanig maron</u>	FY20	FY21	FY22E	FY23E
Paid-up Capital	831	832	832	832
Reserves & Surplus	154,157	174,149	198,050	235,444
Total Equity	154,988	174,981	198,882	236,276
Total Debt	22,102	30,308	30,308	30,308
Other non-current liab.	2,860	2,401	2,401	2,401
Capital Employed	179,950	207,690	231,591	268,985
Total Cur. Lia. & Prov.	52,016	57,463	60,597	70,585
Total Liabilities	231,966	265,153	292,188	339,570
Net Fixed Assets	83,985	97,327	96,372	95,168
Deferred tax asset	11,939	10,292	10,292	10,292
Investments	3,091	8,333	8,333	8,333
Inventory	35,066	45,412	43,337	51,097
Debtors	50,278	49,641	55,658	65,625
Other Current Assets	21,867	19,575	21,267	24,366
Cash and Equivalents	25,740	34,573	56,930	84,689
Total Cur. Assets	132,951	149,201	177,191	225,777
Total Assets	231,966	265,153	292,188	339,570

Source: Company data, I-Sec research

## **Table 6: Cashflow statement**

(Rs mn,	year ending March 31)	
		FV2

	FY20	FY21	FY22E	FY23E
PBT (Adj. for EO items)	18,031	28,324	40,490	63,347
Depreciation	12,472	12,696	12,955	13,204
Net Chg in WC	(12,357)	(4,939)	(4,688)	(15,359)
Taxes	(7,105)	(5,716)	(10,122)	(15,837)
Others	17,192	5,338	2,188	4,521
CFO	28,233	35,703	40,823	49,876
Capex	(5,725)	(27,990)	(12,000)	(12,000)
Net Investments made	(214)	4,110	-	-
Others	1,016	1,220	-	-
CFI	(4,923)	(22,660)	(12,000)	(12,000)
Change in Share capital	4	269	-	-
Change in Debts	(19,165)	1,947	-	-
Div. & Div Tax	(3,916)	(4,147)	(6,466)	(10,116)
Others	(408)	1,664	-	-
CFF	(23,485)	(267)	(6,466)	(10,116)
Total Cash Generated	(175)	12,776	22,357	27,760
Cash Opening Balance	2,228	2,053	14,829	37,186
Cash Closing Balance	2,053	14,829	37,186	64,945
Source: Company data, I-Sec	research			

Source: Company data, I-Sec research

# Table 7: Key ratios

#### (Year ending March 31)

(Tour chung march ST)				
	FY20	FY21	FY22E	FY23E
Adj EPS (Rs)	112.0	156.1	182.9	286.2
yoy Growth%	9.7	39.4	17.2	56.5
Cash EPS (Rs)	187.1	232.6	261.0	365.7
EBITDA - Core (%)	21.1	23.5	23.9	29.6
NPM (%)	11.1	13.7	14.4	19.2
Net Debt to Equity (x)	(0.0)	(0.0)	(0.1)	(0.2)
P/E (x)	46.4	33.3	28.4	18.2
EV/EBITDA Core (x)	24.3	19.2	16.6	11.0
P/BV (x)	5.6	4.9	4.3	3.7
EV/Sales (x)	5.1	4.5	4.0	3.3
ROCE (%)	10.3	13.4	13.8	19.0
ROE (%)	12.6	15.7	16.2	21.8
ROIC (%)	11.9	15.8	17.4	26.4
Book Value (Rs)	933.7	1,054.1	1,198.1	1,423.4
DPS (Rs)	20.7	25.0	32.3	50.6
Dividend Payout (%)	17.7	21.7	17.7	17.7
Div Yield (%)	0.4	0.5	0.6	1.0
Asset Turnover Ratio	0.7	0.8	0.8	0.8
Avg Collection days	97	97	97	97
Avg Inventory days	75	75	75	75

Source: Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet\_babbar@icicisecuritiesinc.com, Rishi agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors.

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise) BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

#### ANALYST CERTIFICATION

I/We, Sriraam Rathi, CA; Vinay Bafna, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number - INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be

subject to change without notice. ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives on ot own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.